Single-nucleus profiling of postmortem diffuse midline gliomas treated with dordaviprone/imipridone identified mitochondrial
biogenesis as a treatment-resistance program. Functional studies nominate metabolic vulnerabilities for future combination strategies.
A collaborative Neuro-Oncology study maps the cellular and immune changes associated with MAPK-driven glioma
progression. The work integrates molecular and spatial analyses to identify tumor-intrinsic and microenvironmental programs associated with aggressive disease.
A multi-institutional study evaluated vectorized cytokine delivery as an AAV immuno-gene therapy platform for high-grade glioma. The work establishes a translational framework for sustained local immunomodulation.
Clinical and translational results from PNOC005 were
published in Clinical Cancer Research. Diaz Lab investigators
contributed single-cell, spatial, and functional studies that
characterized response and resistance to oncolytic-virus
therapy.
A collaborative study demonstrated that recurrent RNA-splicing
aberrations can generate shared tumor antigens across
patients and cancer types. The findings create a foundation for
broadly applicable T-cell-based therapeutic strategies.
A UCSF collaboration integrated genomics, epigenomics,
pathology, imaging, and clinical outcomes across longitudinal
glioblastoma specimens. The study identified molecular and
cellular features associated with prognostically distinct
responses.
UCSF Researchers Identify the Cellular Source of Recurrent Glioma
UCSF Brain Tumor Center
